Everolimus Plus Exemestane Treatment in Patients with Metastatic Hormone Receptor-Positive Breast Cancer Previously Treated with CDK4/6 Inhibitor Therapy.
Madeline M CookLuai Al RabadiAndy J KaempfMegan M SaraceniMichael A SavinZahi I MitriPublished in: The oncologist (2020)
The use of CDK4/6 inhibitors in combination with a nonsteroidal aromatase inhibitor has become a standard frontline therapy in metastatic hormone receptor-positive breast cancer. An approved subsequent line of therapy is everolimus plus exemestane; however, the original data supporting this therapy predated approval of CDK4/6 inhibitors. As such, the clinical benefit of everolimus and exemestane in patients previously treated with a CDK4/6 inhibitor was unknown. This retrospective cohort study offers real-world data demonstrating prior CDK4/6 inhibitor exposure does not impact survival outcomes for everolimus plus exemestane.
Keyphrases
- positive breast cancer
- cell cycle
- squamous cell carcinoma
- metastatic breast cancer
- end stage renal disease
- newly diagnosed
- small cell lung cancer
- big data
- electronic health record
- chronic kidney disease
- ejection fraction
- cell proliferation
- bone marrow
- cell therapy
- artificial intelligence
- patient reported outcomes
- data analysis
- drug administration